N-boc-L-苏氨酸 | 45214-52-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-boc-L-苏氨酸
• 中文别名: O-乙酰基-N-(叔丁氧羰基)-L-苏氨酸
• 英文名称: Boc-Thr(Ac)-OH
• 英文别名: (2S,3R)-3-Acetoxy-2-((tert-butoxycarbonyl)amino)butanoic acid；(2S,3R)-3-acetyloxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• CAS: 45214-52-6
• 化学式: C₁₁H₁₉NO₆
• 分子量: 261.275
• InChiKey: ZBDQHSHVSLIFAR-SVRRBLITSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-boc-L-苏氨酸 在 palladium on activated charcoal 盐酸 、 氢气 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 10.0h， 生成 Acetic acid (1R,2S)-2-({(S)-1-[(2S,4S)-4-hydroxy-2-((S)-2-methyl-5-oxo-2,5-dihydro-pyrrole-1-carbonyl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-methyl-carbamoyl)-1-methyl-2-((S)-4-methyl-2-methylamino-pentanoylamino)-ethyl ester; hydrochloride
  参考文献：
  名称：

  Total Asymmetric Synthesis of the Potent Immunosuppressive Marine Natural Product Microcolin A

  摘要：

  The total asymmetric synthesis of the potent immunosuppressive compound microcolin A is reported, The synthesis establishes the absolute stereochemistry of microcolin A as C-36R, C-38R, and C-4S on the basis of the diastereoselective preparation of all four possible diastereomers of the lipid region (fragment A) and diastereoselective synthesis of fragment C starting from natural L-(S)-alanine. The strategy involves a convergent assemblage of three optically pure fragments and is amenable to chemical modifications to examine structural analogs for biological study.

  DOI：

  10.1021/jo952123l
• 作为产物：
  描述：

  Boc-Thr-ONbn 在 palladium on activated charcoal 4-二甲氨基吡啶 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 N-boc-L-苏氨酸
  参考文献：
  名称：

  Towards nucleopeptides containing any trifunctional amino acid

  摘要：

  Nucleopeptides incorporating, besides the linking residue, other trifunctional amino acids such as lysine, arginine, tryptophan, serine, threonine and tyrosine have been obtained following stepwise solid-phase assembly. The best alternatives for the protection of the side chains of these trifunctional amino acids are discussed. The use of different solid supports (polystyrene-co-1%-divinylbenzene, controlled pore glass and polyethylene glycol-polystyrene) and nucleopeptide-resin linkers has also been evaluated. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00815-7

文献信息

• Highly Convergent Total Synthesis and Assignment of Absolute Configuration of Majusculamide D, a Potent and Selective Cytotoxic Metabolite from <i>Moorea sp.</i>
  作者：Eduardo J. E. Caro-Diaz、Frederick A. Valeriote、William H. Gerwick

  DOI：10.1021/acs.orglett.8b04050

  日期：2019.2.1

  The total synthesis of majusculamide D (MJS-D) is described, a lipopentapeptide originally isolated from Lyngbya majuscula and reisolated from a Moorea sp. MJS-D possesses selective and potent cancer cell toxicity. A scalable and convergent strategy with a minimal number of purifications produced significant quantities of MJM-D for in vivo evaluations. The absolute configuration of the 1,3-dimethyl-octanamide

  描述了Majusculamide D（MJS-D）的总合成，一种脂五肽最初从Lyngbya majuscula分离出来，然后从Moorea sp。中分离出来。MJS-D具有选择性和有效的癌细胞毒性。具有最少纯化次数的可扩展且收敛的策略可产生大量MJM-D用于体内评估。通过经由ZACA化学合成该片段来确定1，3-二甲基-辛酰胺基序的绝对构型。
• 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和NMDA调节剂的药物组合
  申请人：西北大学

  公开号：CN108601814A

  公开（公告）日：2018-09-28

  本公开的特征在于NMDA调节剂和非典型抗精神病药的组合。本公开提供例如治疗有需要的患者的精神分裂症、双相障碍和/或认知损害病症的方法，其包括施用例如雷帕替奈和非典型抗精神病药。
• NMDA Receptors Modulators and Uses Thereof
  申请人：Moskal Joseph

  公开号：US20130035292A1

  公开（公告）日：2013-02-07

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强效力的化合物，其可调节NMDA受体活性。这样的化合物可用于治疗疾病和疾病，如学习、认知活动和镇痛，特别是减轻和/或减少神经病理性疼痛。本发明还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉给药制剂。
• NMDA receptors modulators and uses thereof
  申请人：Moskal Joseph

  公开号：US08673843B2

  公开（公告）日：2014-03-18

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节效能的化合物。这样的化合物可用于治疗疾病和疾病，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病性疼痛方面。还揭示了口服制剂和其他药学上可接受的化合物递送形式，包括静脉制剂。
• NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20150051262A1

  公开（公告）日：2015-02-19

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节作用的化合物。这样的化合物被考虑用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病理性疼痛方面。本发明还公开了口服制剂和其他药学可接受的化合物给药形式，包括静脉注射制剂。